Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model

In light of the rising prevalence of Alzheimer’s disease (AD), new strategies to prevent, halt, and reverse this condition are needed urgently. Perturbations of brain network activity are observed in AD patients and in conditions that increase the risk of developing AD, suggesting that aberrant network activity might contribute to AD-related cognitive decline. Human amyloid precursor protein (hAPP) transgenic mice simulate key aspects of AD, including pathologically elevated levels of amyloid-β peptides in brain, aberrant neural network activity, remodeling of hippocampal circuits, synaptic deficits, and behavioral abnormalities. Whether these alterations are linked in a causal chain remains unknown. To explore whether hAPP/amyloid-β–induced aberrant network activity contributes to synaptic and cognitive deficits, we treated hAPP mice with different antiepileptic drugs. Among the drugs tested, only levetiracetam (LEV) effectively reduced abnormal spike activity detected by electroencephalography. Chronic treatment with LEV also reversed hippocampal remodeling, behavioral abnormalities, synaptic dysfunction, and deficits in learning and memory in hAPP mice. Our findings support the hypothesis that aberrant network activity contributes causally to synaptic and cognitive deficits in hAPP mice. LEV might also help ameliorate related abnormalities in people who have or are at risk for AD.

[1]  Amy L. Shelton,et al.  Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment , 2012, Neuron.

[2]  Edward O. Mann,et al.  Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.

[3]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[4]  Kelly O'Keefe,et al.  Hippocampal Hyperactivation Associated with Cortical Thinning in Alzheimer's Disease Signature Regions in Non-Demented Elderly Adults , 2011, The Journal of Neuroscience.

[5]  D. Bredesen,et al.  Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain , 2011, Neurobiology of Aging.

[6]  D. Holtzman,et al.  Opposing Synaptic Regulation of Amyloid-β Metabolism by NMDA Receptors In Vivo , 2011, The Journal of Neuroscience.

[7]  S. Rothman,et al.  A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. , 2011, Journal of neurophysiology.

[8]  Shaomin Li,et al.  Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors , 2011, The Journal of Neuroscience.

[9]  Jee Hoon Roh,et al.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.

[10]  K. Lyseng-Williamson.  Levetiracetam: a review of its use in epilepsy. , 2011, Drugs.

[11]  H. Tanila,et al.  Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels , 2011, Epilepsy Research.

[12]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[13]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[14]  Julie Harris,et al.  Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.

[15]  Erik D Roberson,et al.  Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling. , 2011, Methods in molecular biology.

[16]  Julie A. Harris,et al.  Transsynaptic Progression of Amyloid-β-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network , 2010, Neuron.

[17]  S. Kar,et al.  β-Amyloid-related peptides potentiate K+-evoked glutamate release from adult rat hippocampal slices , 2010, Neurobiology of Aging.

[18]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[19]  Todd E. Golde,et al.  Targeting Aβ and tau in Alzheimer's disease, an early interim report , 2010, Experimental Neurology.

[20]  E. Cumbo,et al.  Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease , 2010, Epilepsy & Behavior.

[21]  E. Aronica,et al.  Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.

[22]  Michela Gallagher,et al.  Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment , 2010, Neuropsychopharmacology.

[23]  G. D. Paolo,et al.  Faculty Opinions recommendation of Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. , 2010 .

[24]  I. Bezprozvanny,et al.  The dysregulation of intracellular calcium in Alzheimer disease. , 2010, Cell calcium.

[25]  R. Scott,et al.  Hippocampal interictal spikes disrupt cognition in rats , 2010, Annals of neurology.

[26]  Julie A. Harris,et al.  Many Neuronal and Behavioral Impairments in Transgenic Mouse Models of Alzheimer's Disease Are Independent of Caspase Cleavage of the Amyloid Precursor Protein , 2010, The Journal of Neuroscience.

[27]  M. Bialer,et al.  Key factors in the discovery and development of new antiepileptic drugs , 2010, Nature Reviews Drug Discovery.

[28]  Keith A. Johnson,et al.  Functional Alterations in Memory Networks in Early Alzheimer’s Disease , 2010, NeuroMolecular Medicine.

[29]  S. Rothman,et al.  Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission , 2009, Seizure.

[30]  Keith A. Johnson,et al.  Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.

[31]  Shaomin Li,et al.  Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.

[32]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[33]  Sylvain Rheims,et al.  Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy , 2009, The Journal of Neuroscience.

[34]  I. Bezprozvanny.  Calcium signaling and neurodegenerative diseases. , 2009, Trends in molecular medicine.

[35]  T. Südhof,et al.  SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis , 2009, The Journal of Neuroscience.

[36]  F. H. Lopes da Silva,et al.  Development of tolerance to levetiracetam in rats with chronic epilepsy , 2008, Epilepsia.

[37]  Guojun Bu,et al.  Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.

[38]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[39]  L. Mucke,et al.  Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models* , 2007, Journal of Biological Chemistry.

[40]  L. Willmore,et al.  Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection , 2007, Brain Research.

[41]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[42]  R. Raedt,et al.  Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. , 2007, CNS drug reviews.

[43]  R. Raedt,et al.  Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. , 2007, CNS drug reviews.

[44]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[45]  Vince D. Calhoun,et al.  Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer's Disease: An Independent Component Analysis , 2006, The Journal of Neuroscience.

[46]  Dieter Schmidt,et al.  Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs , 2006, Epilepsia.

[47]  Jean Gotman,et al.  EEG–fMRI of epileptic spikes: Concordance with EEG source localization and intracranial EEG , 2006, NeuroImage.

[48]  J. Gotman,et al.  Temporal and Extratemporal BOLD Responses to Temporal Lobe Interictal Spikes , 2006, Epilepsia.

[49]  N. S. Austin,et al.  Synaptic Vesicle Protein 2 Enhances Release Probability at Quiescent Synapses , 2006, The Journal of Neuroscience.

[50]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[51]  L. Mucke,et al.  Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[52]  M. Albert,et al.  Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD , 2005, Neurology.

[53]  Xiao-Min Wang,et al.  Effects of distinct classes of N-methyl-d-aspartate receptor antagonists on seizures, axonal sprouting and neuronal loss in vitro: suppression by NR2B-selective antagonists , 2004, Neuropharmacology.

[54]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Binnie,et al.  Cognitive impairment during epileptiform discharges: is it ever justifiable to treat the EEG? , 2003, The Lancet Neurology.

[56]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[57]  Jacob Raber,et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[59]  E. Ben-Menachem,et al.  Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons , 2003, Neuroreport.

[60]  Josemir W Sander,et al.  Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy , 2003, Epilepsy Research.

[61]  M. Mendez,et al.  Seizures in Elderly Patients with Dementia , 2003, Drugs & aging.

[62]  W. Löscher,et al.  Effects of the Novel Antiepileptic Drug Levetiracetam on Spontaneous Recurrent Seizures in the Rat Pilocarpine Model of Temporal Lobe Epilepsy , 2002, Epilepsia.

[63]  N. Danbolt.  Glutamate uptake , 2001, Progress in Neurobiology.

[64]  Patrick Kwan,et al.  Neuropsychological effects of epilepsy and antiepileptic drugs , 2001, The Lancet.

[65]  W. Löscher,et al.  Development of Tolerance During Chronic Treatment of Kindled Rats With the Novel Antiepileptic Drug Levetiracetam , 2000, Epilepsia.

[66]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[67]  M R Symms,et al.  EEG-triggered functional MRI of interictal epileptiform activity in patients with partial seizures. , 1999, Brain : a journal of neurology.

[68]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[69]  L. Mucke,et al.  Levels and Alternative Splicing of Amyloid β Protein Precursor (APP) Transcripts in Brains of APP Transgenic Mice and Humans with Alzheimer's Disease (*) , 1995, The Journal of Biological Chemistry.